Your browser doesn't support javascript.
loading
S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3.
Schonthaler, Helia B; Guinea-Viniegra, Juan; Wculek, Stefanie K; Ruppen, Isabel; Ximénez-Embún, Pilar; Guío-Carrión, Ana; Navarro, Raquel; Hogg, Nancy; Ashman, Keith; Wagner, Erwin F.
Afiliação
  • Schonthaler HB; BBVA Foundation-CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Guinea-Viniegra J; BBVA Foundation-CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Wculek SK; BBVA Foundation-CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Ruppen I; Proteomics Unit, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Ximénez-Embún P; Proteomics Unit, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Guío-Carrión A; BBVA Foundation-CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Navarro R; Department of Dermatology, Hospital Universitario La Princesa, 28006 Madrid, Spain.
  • Hogg N; Leukocyte Adhesion Laboratory, London Research Institute, Cancer Research UK, London WC2A 3LY, UK.
  • Ashman K; Proteomics Unit, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain.
  • Wagner EF; BBVA Foundation-CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), 29029 Madrid, Spain. Electronic address: ewagner@cnio.es.
Immunity ; 39(6): 1171-81, 2013 Dec 12.
Article em En | MEDLINE | ID: mdl-24332034
ABSTRACT
Psoriasis is a common heterogeneous inflammatory skin disease with a complex pathophysiology and limited treatment options. Here we performed proteomic analyses of human psoriatic epidermis and found S100A8-S100A9, also called calprotectin, as the most upregulated proteins, followed by the complement component C3. Both S100A8-S100A9 and C3 are specifically expressed in lesional psoriatic skin. S100A9 is shown here to function as a chromatin component modulating C3 expression in mouse and human cells by binding to a region upstream of the C3 start site. When S100A9 was genetically deleted in mouse models of skin inflammation, the psoriasis-like skin disease and inflammation were strongly attenuated, with a mild immune infiltrate and decreased amounts of C3. In addition, inhibition of C3 in the mouse model strongly reduced the inflammatory skin disease. Thus, S100A8-S100A9 can regulate C3 at the nuclear level and present potential new therapeutic targets for psoriasis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Complemento C3 / Regulação da Expressão Gênica / Calgranulina A / Calgranulina B Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Complemento C3 / Regulação da Expressão Gênica / Calgranulina A / Calgranulina B Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2013 Tipo de documento: Article